ESMO 2024: Promising results in immunotherapy and antibody drug conjugates for gynecological cancers
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a…